Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1999-11-04
2002-03-19
Fonda, Kathleen K. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S053000, C514S054000, C514S061000, C424S499000
Reexamination Certificate
active
06358930
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to treatment of antibiotic associated diarrhea, including
Clostridium difficile
associated diarrhea (CDAD) and pseudomembranous colitis (PMC) and other conditions associated with
C. difficile
infection. More specifically, the invention concerns neutralization of
C. difficile
toxin B, a cytotoxin associated with CDAD, PMC and other conditions caused by
C. difficile.
REFERENCES
The following references are cited in the application as numbers in brackets ([]) at the relevant portion of the application.
1. Bartlett, J. G., et al., “Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia”,
N. Engl. J. Med
., 298:531-534 (1978).
2. Lyerly, D. M., “Epidemiology of
Clostridium difficile
disease”,
Clin. Microbiol. News
, 15:49-53 (1993).
3. Cozart, J. C., et al., “
Clostridium difficile
diarrhea in patients with AIDS versus non-AIDS controls. Method of treatment and clinical response to treatment”,
J. Clin. Gastroenterol
., 16:192-4 (1993).
4. Barbut, F., et al., “Comparison of Enterotoxin Production, cytotoxin production, serogrouping and antimicrobial susceptibilities of
Clostridium difficile
strains isolated from AIDS and human immunodeficiency virus-negative patients”,
J. Clin. Microbiol
., 31:740-2 (1993).
5. Krivan, H. C., et al., “Cell surface binding site for
Clostridium difficile
enterotoxin: evidence for a glycoconjugate containing the sequence &agr;Gal(1-3)&bgr;Gal(1-4)&bgr;GlcNAc”,
Infect. Immun
., 53:573-81 (1986).
6. Clark, G. F., et al., “Toxin A from
Clostridium difficile
binds to rabbit erythrocyte glycolipids with terminal &agr;Gal(1-3)&bgr;Gal(1-4)&bgr;GlcNAc sequences”,
Arch. Biochem. Biophys
., 257:217-29 (1987).
7. Tucker, K. D., et al., “Toxin A of
Clostridium difficile
binds to carbohydrate antigens I, X, and Y”,
Infect. Immun
., 59:73-8 (1991).
8. Krivan, H. C., et al., “Purification of
Clostridium difficile
toxin A by affinity chromatography on immobilized bovine thyroglobulin”,
Infect. Immun
., 55:1873-7 (1987).
9. Kamiya, S., et al., “Analysis of purity of
Clostridium difficile
toxin A derived by affinity chromatography on immobilized bovine thyroglobulin”,
FEMS Microbiol. Lett
., 56:331-6 (1988).
10. Armstrong, G. D., et al., “Investigation of shiga-like toxin binding to chemically synthesized oligosaccharide sequences”,
J. Infect. Dis
., 164:1160-7 (1991).
11. Von Eichel-Streiber, C., et al., “
Clostridium difficile
toxin A carries a c-terminal repetitive structure homologous to the carbohydrate binding region of streptococcal glycosyltransferases”,
Gene
, 96:107-13 (1990).
12. Lemieux, R. U., et al., “The properties of a ‘synthetic’ antigen related to the blood-group Lewis A”,
J. Am. Chem. Soc
., 97:4076-83 (1975).
13. Sullivan, N. M., et al., “Purification and characterization of toxin A and B from
Clostridium difficile”, Infect. Immun
., 35:1032-40 (1983).
14. Finegold, S. M., et al., “Therapy directed against
Clostridium difficile
and its toxins. Complications of therapy”. In Rolfe, R. D., et al., (eds)
C. difficile
: It's Role in Intestinal Disease, Academic Press, Inc., San Diego, Calif., 341-57 (1988).
15. Bartlett, J. G., et al., “Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis”,
Gastroenterology
, 78:431-4 (1989).
16. Tedesco, F. J., “Pseudomembranous colitis: Pathogenesis and therapy”,
Med. Clin. North Am
., 66:655-64 (1982).
17. Keighley, M. R. B., “Antibiotic-associated pseudomembranous colitis: pathogenesis and management”,
Drugs
, 20:449-56 (1980).
18. Bartlett, J. D., “Treatment of antibiotic-associated pseudomembranous colitis”,
Rev. Infect. Dis
., 6, Suppl. 1:1-55 (1984).
19. Onderdonk, A. B., et al., “Comparative effects of clindamycin and clindamycin metabolites in the hamster model for antibiotic-associated colitis”,
J. Antimicrob. Chem
., 8:383-93 (1981).
20. Triadfilopoulos, G., et al., “Differential effects of
Clostridium difficile
toxin a and b on rabbit ileum”,
Gastroenterology
, 93:273-9 (1987).
21. Lemieux, R. U., et al., “Glycoside-Ether-Ester Compounds”, U.S. Pat. No. 4,137,401, issued Jan. 30, 1979.
22. Lemieux, R. U., et al., “Artificial Oligosaccharide Antigenic Determinants”, U.S. Pat. No. 4,238,473, issued Dec. 9, 1980.
23. Lemieux, R. U., et al., “Synthesis of 2-Amino-2-Deoxyglycoses and 2-Amino-2-Deoxyglycosides from glycals”, U.S. Pat. No. 4,362,720, issued Dec. 7, 1982.
24. Cox, D., et al. “A New Synthesis of 4-0-&agr;-D-Galactopyranosyl-D-Galacto-Pyranose”,
Carbohy. Res
., 62: 245-252 (1978).
25. Dahmén, J., et al., “Synthesis of space arm, lipid, and ethyl glycosides of the trisaccharide portion [&agr;-D-Gal-(1-4)-&bgr;-D-Gal(1-4)-&bgr;-D-Glc] of the blood group p
k
antigen: preparation of neoglycoproteins”,
Carbohy. Res
., 127: 15-25 (1984).
26. Garegg, P. J., et al., “A Synthesis of 8-Methoxycarbonyloct-1-yl O-&agr;-D-Galactopyranosyl-(1→3)-0-&bgr;-D-Galactopyranosyl-(1→4)-2-Acetamido-2-Deoxy-&bgr;-D-Glucopyranoside”,
Carbohy. Res
., 136: 207-213 (1985).
27. Garegg, P. J., et al., “Synthesis of 6- and 6′-deoxy derivatives of methyl 4-0-&agr;-D-galactopyranosyl-&bgr;-D-galactopyranoside for studies of inhibition of pyelonephritogenic fimbriated
E. coli
adhesion to urinary epithelium-cell surfaces”,
Carbohy. Res
., 137: 270-275 (1985).
28. Jacquinet, J. C., et al., “Synthesis of Blood-group Substances, Part 11. Synthesis of the Trisaccharide O-&agr;-D-Galactopyranosyl-(1→3)-0-&bgr;-D-galactopyranosyl-(1-4)-2-acetamido-2-deoxy-D-glucopyranose”,
J. C. S. Perkin
, 1:326-330 (1981).
29. Koike, K., et al., “Total Synthesis of Globotriaosyl-E and Z-Ceramides and Isoglobotriaosyl-E-Ceramide,”
Carbohy. Res
., 163: 189-208 (1987).
30. Schaubach, R., et al., “Tumor-Associated Antigen Synthesis: Synthesis of the Gal-&agr;-(1→3)-Gal-&bgr;-(1→4)-GlCNAc Epitope. A specific Determinant for Metastatic Progression?,”
Liebigs Ann. Chem
., 607-614 (1991).
31. Ratcliffe, R. M., et al., “Sialic Acid Glycosides, Antigens, Immunoadsorbents, and Methods for Their Preparation”, U.S. Pat. No. 5,079,353, issued Jan. 7, 1992.
32. Okamoto, K., et al., “Glycosidation of Sialic Acid,”
Tetrahedron
, 47: 5835-5857 (1990).
33. Abbas, S. A., et al., “Tumor-Associated Oligosaccharide I: Synthesis of Sialyl-Lewis
a
Antigenic Determinant”,
Sialic Acids, Proc
. Japan-German Symp. Berlin, 22-23 (1988).
34. Paulsen, “Advances in Selective Chemical Syntheses of Complex Oligosaccharide”, Angew.
Chem. Int. Ed. Eng
., 21:155-173 (1982).
35. Schmidt, “New Methods for the Synthesis of Glycosides and Oligosaccharide—Are There Alternatives to the Koenigs-Knorr Method?”
Angew. Chem. Int. Ed. Eng
., 25:212-235 (1986).
36. Fügedi, P., et al., “Thioglycosides as Glycosylating Agents in Oligosaccharide Synthesis”,
Glycoconjugate J
., 4:97-108 (1987).
37. Kameyama, A., et al., “Total synthesis of sialyl Lewis X”,
Carbohy. Res
., 209: c1-c4 (1991).
38. Ekborg, G., et al., “Synthesis of Three Disaccharides for the Preparation of Immunogens bearing Immunodeterminants Known to Occur on Glycoproteins”,
Carbohy. Res
., 110: 55-67 (1982).
39. Dahmén, J., et al., “2-Bromoethyl glycosides: applications in the synthesis of spacer-arm glycosides,”
Carbohy. Res
., 118: 292-301 (1983).
40. Rana, S. S., et al., “Synthesis of Phenyl 2-Acetamido-2-Deoxy-3-O-&agr; L-Fucopyranosyl-&bgr;-D-Glucopyranoside and Related Compounds”,
Carbohy. Res
., 91: 149-157 (1981).
41. Amvam-Zollo, P., et al., “Streptococcus pneumoniae Type XIV Polysaccharide: Synthesis of a Repeating Branched Tetrasaccharide with Dioxa-Type Spacer-Arms”,
Carbohy. Res
., 150:199-212 (1986).
42. Paulsen, H., “Synthese von oligosaccharid-determinanten mit amid-spacer vom typ des T-antigens”,
Carbohy. Res
., 104:195-219 (1982).
43. Chernyak, A. Y., et al., “A New Type of Carbohydrate-Containing Synthetic Antigen: Synthesis of Carbohydrate-Containing Polyacrylamide Copolymers having the Specificity of 0:3 and 0:4 Factors of Salmonella”, Carbohy. Res., 128: 269-282 (1984)
Armstrong Glen D.
Heerze Louis D.
Burns Doane , Swecker, Mathis LLP
Fonda Kathleen K.
Synsorb Biotech Inc.
LandOfFree
Treatment of C. difficile toxin B associated conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of C. difficile toxin B associated conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of C. difficile toxin B associated conditions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2850585